ATE243520T1 - Durch hydroxylierung aktivierte wirkstofffreigabe - Google Patents

Durch hydroxylierung aktivierte wirkstofffreigabe

Info

Publication number
ATE243520T1
ATE243520T1 AT99905005T AT99905005T ATE243520T1 AT E243520 T1 ATE243520 T1 AT E243520T1 AT 99905005 T AT99905005 T AT 99905005T AT 99905005 T AT99905005 T AT 99905005T AT E243520 T1 ATE243520 T1 AT E243520T1
Authority
AT
Austria
Prior art keywords
hydroxylation
active release
release activated
aromatic
prodrugs
Prior art date
Application number
AT99905005T
Other languages
English (en)
Inventor
Gerard Andrew Potter
Lawrence Hylton Patterson
Lane Anstey Gynsill
Michael Danny Burke
Original Assignee
Univ Montfort
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9802957A external-priority patent/GB2334256A/en
Application filed by Univ Montfort filed Critical Univ Montfort
Application granted granted Critical
Publication of ATE243520T1 publication Critical patent/ATE243520T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT99905005T 1998-02-12 1999-02-10 Durch hydroxylierung aktivierte wirkstofffreigabe ATE243520T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9802957A GB2334256A (en) 1998-02-12 1998-02-12 Hydroxylation activated prodrugs
US09/115,016 US20020037296A1 (en) 1998-02-12 1998-07-14 Hydroxylation activated drug release
PCT/GB1999/000416 WO1999040944A2 (en) 1998-02-12 1999-02-10 Hydroxylation activated drug release

Publications (1)

Publication Number Publication Date
ATE243520T1 true ATE243520T1 (de) 2003-07-15

Family

ID=26313102

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99905005T ATE243520T1 (de) 1998-02-12 1999-02-10 Durch hydroxylierung aktivierte wirkstofffreigabe

Country Status (6)

Country Link
EP (1) EP1069915B1 (de)
AT (1) ATE243520T1 (de)
AU (1) AU2531599A (de)
CA (1) CA2319837C (de)
DE (1) DE69909073T2 (de)
WO (1) WO1999040944A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2226332T3 (es) 1998-02-06 2005-03-16 De Montfort University Profarmacos activados mediante hidroxilacion.
GB2334256A (en) 1998-02-12 1999-08-18 Univ Montfort Hydroxylation activated prodrugs
GB9828670D0 (en) 1998-12-24 1999-02-17 Univ Montfort Anthraquinone anticancer drugs
UA95788C2 (en) 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
WO2010057515A1 (en) * 2008-11-21 2010-05-27 Synthon B.V. Levocetirizine by menthyl intermediate
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
US8927760B2 (en) * 2010-02-18 2015-01-06 The Asan Foundation Colchicine derivatives or pharmaceutically acceptable salts thereof, method for preparing said derivatives, and pharmaceutical composition comprising said derivatives
US8846723B2 (en) 2010-07-29 2014-09-30 Eastman Chemical Company Esters of O-substituted hydroxy carboxylic acids and preparations thereof
CN103524349B (zh) * 2013-10-19 2015-09-09 山东大学 Ca-4碳酸酯类衍生物、其制备方法、药物组合物与医药用途
PE20210367A1 (es) 2018-02-02 2021-02-26 Maverix Oncology Inc Conjugados de farmacos de molecula pequena de monofosfato de gemcitabina
EP3746133A1 (de) 2018-02-02 2020-12-09 Maverix Oncology, Inc. Neuartige kleinmolekülige wirkstoffkonjugate aus gemcitabin-derivaten

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773435A (en) * 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
DE4309344A1 (de) * 1993-03-23 1994-09-29 Gerhard Prof Dr Eisenbrand Antineoplastische Mittel mit verstärkter Wirksamkeit
EP0647450A1 (de) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Verbesserte Prodrogen für Enzym-vermittelten-Aktivierungen

Also Published As

Publication number Publication date
EP1069915B1 (de) 2003-06-25
CA2319837A1 (en) 1999-08-19
EP1069915A2 (de) 2001-01-24
DE69909073T2 (de) 2004-05-19
WO1999040944A3 (en) 1999-09-23
WO1999040944A2 (en) 1999-08-19
DE69909073D1 (de) 2003-07-31
AU2531599A (en) 1999-08-30
CA2319837C (en) 2009-10-27

Similar Documents

Publication Publication Date Title
ATE272040T1 (de) Durch hydroxylierung aktivierte medikamentvorstufen
ATE243520T1 (de) Durch hydroxylierung aktivierte wirkstofffreigabe
ATE438724T1 (de) Chemisch modifizierte enzymen mit mehrfachgeladenen varianten
WO1999043651A3 (en) Inhibitors of phospholipase enzymes
PL352021A1 (en) Agent having advantageous effect on ketose
EP1818396A3 (de) Alpha-Amylase Varianten
MXPA02002901A (es) Enzimas de ruta de enfocado lisosomal.
DK1660650T3 (da) Forbedrede Sso7-polymerase-konjugat-proteiner
WO2006063055A3 (en) Enzyme conjugates for use as detoxifying agents
ATE553185T1 (de) Expressionskassette und vektor zur transienten oder stabilen expression exogener moleküle
SE0202705D0 (en) Supported Disc
ATE493106T1 (de) Oberflächenbehandlungsmittel für dentales hartgewebe
DK1095032T3 (da) Hidtil ukendte fluorescerende CYP2D-assayreagenser
AU2002220697A1 (en) Isolated luciferases lu164, lual and lu22, and the use of the same
HK1045496A1 (en) Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity
ATE418613T1 (de) Antimikrobielle zusammensetzungen
PT1289562E (pt) Novo preparado de hipericina com poli-n-vinilamidas
NO20014260L (no) Flerkomponentsystem for enzymkatalysert oksidasjon av substrater, og fremgangsmåter for enzymkatalysert oksidasjon
DE60022083D1 (de) Neutralisierungsmittel für toxin der zur gattung clostridium gehörende mikroorganismen
HUP9904408A2 (hu) Lactobacillus vakcina prosztatagyulladás és jóindulatú prostatahyperplasia kezelésére
PT1196606E (pt) Enzima litica
WO2002053171A3 (de) Verwendung von 'intermediate-conductance kaliumkanälen und modulatoren zur diagnose und behandlung von krankheiten mit gestörter keratinozytenaktivität
Poulose High bio detergents
AU3178700A (en) Enzymatically catalysed signal amplification
WO2002007780A3 (en) Methods for identifying therapeutic targets

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties